- Home
- PPIH vs CHRS Comparison
PPIH vs CHRS Comparison
Compare PPIH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPIH
- CHRS
- Stock Information
- Founded
- PPIH 1993
- CHRS 2010
- Country
- PPIH United States
- CHRS United States
- Employees
- PPIH N/A
- CHRS N/A
- Industry
- PPIH Pollution Control Equipment
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPIH Industrials
- CHRS Health Care
- Exchange
- PPIH Nasdaq
- CHRS Nasdaq
- Market Cap
- PPIH 189.6M
- CHRS 186.0M
- IPO Year
- PPIH N/A
- CHRS 2014
- Fundamental
- Price
- PPIH $24.99
- CHRS $1.28
- Analyst Decision
- PPIH
- CHRS Strong Buy
- Analyst Count
- PPIH 0
- CHRS 4
- Target Price
- PPIH N/A
- CHRS $4.51
- AVG Volume (30 Days)
- PPIH 75.5K
- CHRS 1.5M
- Earning Date
- PPIH 12-22-2025
- CHRS 11-06-2025
- Dividend Yield
- PPIH N/A
- CHRS N/A
- EPS Growth
- PPIH N/A
- CHRS N/A
- EPS
- PPIH 1.25
- CHRS 1.34
- Revenue
- PPIH $181,198,000.00
- CHRS $277,728,000.00
- Revenue This Year
- PPIH $25.58
- CHRS N/A
- Revenue Next Year
- PPIH $8.72
- CHRS $109.48
- P/E Ratio
- PPIH $19.57
- CHRS $0.96
- Revenue Growth
- PPIH 14.90
- CHRS 152.07
- 52 Week Low
- PPIH $8.81
- CHRS $0.71
- 52 Week High
- PPIH $33.09
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- PPIH 47.78
- CHRS 43.93
- Support Level
- PPIH $23.01
- CHRS $1.09
- Resistance Level
- PPIH $25.22
- CHRS $1.25
- Average True Range (ATR)
- PPIH 1.25
- CHRS 0.12
- MACD
- PPIH -0.27
- CHRS -0.01
- Stochastic Oscillator
- PPIH 38.11
- CHRS 36.27
About PPIH Perma-Pipe International Holdings Inc.
Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in the reportable segment of Piping Systems. The company engineers, designs, manufactures, and sells specialty piping systems and leak detection systems. Specialty piping systems include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids, and petroleum products, and the coating and insulation of oil and gas gathering and transmission pipelines. It operates in the United States, Canada, the Middle East, Europe, India, and other countries.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.